Pharmaceuticals

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

With promising clinical data and a streamlined FDA path, a smarter molecule could finally offer a better, more tolerable treatment for idiopathic pulmonary fibrosis.

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

BlackRock has once again boosted its holding in Finnish drugmaker Orion to over 5%. We decode what this calculated move signals for Orion's future.

B. Braun's new ready-to-activate antibiotic system promises to save time, reduce errors, and streamline care. Here's how it could reshape hospital efficiency.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

A new alliance aims to streamline at-home diagnostics for pharma, but who is accountable for patient data and safety in this rapidly growing market?

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

New clinical data on VALTOCO nasal spray shows significant benefits for young children, reinforcing the critical need for rapid seizure intervention.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

For the seventh year, Aptar is named a top responsible company. Beyond the award, this is a look at how sustained ESG strategy creates a powerful competitive advantage.

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

Tigerlily Foundation and Bristol Myers Squibb are using brunch to address dire racial disparities in clinical trials. Is this the future of health equity?

A new partnership brings Yamaha's AI-powered robotics to Nikon's imaging labs, creating a hub to accelerate U.S. drug research. Here's the strategy.

Gartner's inaugural 4PL Magic Quadrant names Redwood a Visionary, highlighting how tech-driven logistics are reshaping healthcare supply chain resilience.

A leadership shift at a regional financial powerhouse offers a compelling case study on strategy, innovation, and stakeholder management for biopharma leaders.